AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
A straightforward rationale for incorporating Equal Weighted Indices into a portfolio, emphasizing diversification and simplicity.
22,501 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Bank of America’s macro team expects the Fed to deliver three 25-basis-point hikes this year, pushing rates higher an...
An in-depth look at how much SCHD would be required to replace Social Security income, with current yields, market co...
Tech stocks led the rebound as tensions eased, lifting the Nasdaq while broad indices followed. Here’s what happened,...
New market analysis shows SPXL’s 3x exposure often falls short of its target because of daily resets and volatility d...
JEPI investors missed 13.21% gains in a strong market as an options overlay muted upside and taxes eroded income. Thi...
Prediction markets show divergent odds for Stripe, Discord, and Anduril IPOs as of July 2026. Traders weigh S-1 timin...
AT&T currently yields about 5.3% as its stock slips toward a 52-week low. This piece breaks down whether that high yi...
CleanSpark stock surged after disclosing a $6.6 billion, 20-year data center lease in Georgia, underscoring a shift f...
A dementia diagnosis reshapes retirement plans as custodial care bills far exceed medical costs and Medicare coverage...
Investors often ask where will stock years? BYD’s five-year path holds both promise and risk. This guide breaks down ...
Could Netflix stock fall? This guide delves into the bear case, valuation pressures, and practical steps investors ca...